LUNG CANCER

Jorge Nieva, MD, discusses the backgroup to the IMpower010 study, the results of which were presented at the 2021 American Society of Clinical Oncology Annual Meeting.

Continued efficacy is seen with nivolumab and ipilimumab plus 2 cycles of versus chemotherapy alone for patients with advanced non–small cell lung cancer.

Sustained overall survival and progression-free survival benefits was confirmed following long-term treatment with durvalumab following chemoradation in patients with unresectable stage 3 non-small cell lung cancer whose disease had not progressed after platinum-based concurrent chemoradiotherapy.

After 4 years of treatment with the combination of nivolumab and ipilimumab, the therapy showed durable, long-term overall survival benefit compared with chemotherapy in patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.

Mobocertinib, elicited rapid, deep, and durable responses and demonstrated a tolerable safety profile in patients with platinum-pretreated EGFR exon 20 insertion–positive metastatic non–small cell lung cancer in a phase 1/2 study.

According to results from the phase 1/2 and phase 2 ALTA trials, brigatinib demonstrated sustained long-term responses and survival in patients with crizotinib-refractory ALK-positive non–small cell lung cancer.

Pembrolizumab plus concurrent chemoradiation therapy continues to demonstrate promising antitumor activity in patients with unresectable, locally advanced, stage III non–small cell lung cancer.

In the phase 1/2 ARROW study, pralsentinib was found to be well-tolerated and showed durable responses as treatment of patients with RET fusion-positive non-small cell lung cancer, including those who were not eligible for platinum-based therapy.

Sugemalimab, an anti-PD-L1 antibody, helps to prolong progression-free survival in patients with locally advanced, unrespectable stage III non–small cell lung cancer without disease progression after either concurrent or sequential chemotherapy.

Jared Weiss, MD, shares insight into current unmet needs in extensive-stage small cell lung cancer and provides advice to researchers about the importance of clinical trials studying differential treatments and biomarkers.

Expert oncologist Jared Weiss, MD, considers safety and efficacy data from the ATLANTIS study of lurbinectedin in combination with doxorubicin in relapsed small cell lung cancer.

Thought leader in lung cancer, Jared Weiss, MD, reviews safety and efficacy data from the phase 2 basket trial of lurbinectedin in selected advanced solid tumors.

Key opinion leader in thoracic oncology, Jared Weiss, MD, discusses the role of second-line treatment for relapsed ES-SCLC after first-line therapy and maintenance immunotherapy.

Jared Weiss, MD, reviews first-line treatment options for extensive-stage small cell lung cancer and highlights the current standard-of-care regimen: carboplatin, etoposide, and a PD-L1 inhibitor with the possible addition of trilaciclib.

An expert in the management of lung cancer, Jared Weiss, MD, provides an overview of the initial presentation, clinical work-up, treatment, and follow-up of a 64-year-old woman with extensive-stage small cell lung cancer.

Data collected and analyzed from the Surveillance, Epidemiology, and End Results Medicare database showed that elderly patients with small-cell lung cancer had a substantial burden from myelosuppression events while on chemotherapy.

The FDA has granted accelerated approval to sotorasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA-approved test, who have received at least one prior systemic therapy.

In an interview with Targeted Oncology, Benjamin Levy, MD, discusses the importance of molecular testing in lung cancer, the efficacy and future of targeted therapies, and upcoming practice-changing trials.

During a virtual Targeted Oncology Case-Based Roundtable event, Timothy F. Burns, MD, PHD, discussed the treatment of non–small cell lung cancer based on clinical trial research.

For patients with PD-L1 positive non-small cell lung cancer, qdjuvant treatment with atezolizumab (Tecentriq) led to a significant improvement in disease-free survival (DFS) vs best supportive care.

Chemotherapy for the treatment of non-small cell lung cancer can be quite toxic, however, durvalumab after chemotherapy can help manage toxicities while improving overall survival, according to the PACFIC trial.

The FDA has accepted a biologics license application or sintilimab injection in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with nonsquamous non-small cell lung cancer.

The PACIFIC study included patients with good performance status and unresectable, stage III NSCLC who did not progress after definitive platinum-based chemotherapy with concurrent radiation.

Roy S. Herbst, MD, PhD, discussed the upcoming conference on July 29-31, which will follow a hybrid format with some faculty and attendees participating online and others participating in person.

In an interview with Targeted Oncology, Xiuning Le, MD, PhD, discuss the findings from cohort 5 of the ZENITH20 study including the strategy of splitting the dose in half to reduce adverse events associated with poziotinib.